Key Takeaways
- GSK is acquiring Nuvalent for $10.6 billion in an all-cash transaction at $124 per share — representing a 40% premium over Monday’s closing price
- Shares of GSK declined by as much as 3% during early London trading hours after the acquisition announcement
- Nuvalent’s two flagship therapies target non-small-cell lung cancer and are currently awaiting FDA regulatory decisions scheduled for later in 2026
- The acquisition is projected to contribute to revenue and operating profit starting in 2027, with core earnings per share contribution beginning in 2029
- GSK maintains its 2026 full-year guidance of 7–9% core EPS growth remains unaffected by this transaction
GSK has entered into a definitive agreement to purchase Nuvalent through an all-cash transaction valued at $10.6 billion, offering $124 per share — marking a substantial 40% premium above Nuvalent’s Monday closing price.
GSK stock experienced a decline of up to 3% during early London trading sessions following Tuesday’s deal announcement. Despite this dip, the stock has maintained approximately 23% gains over the trailing twelve months.
Nuvalent’s shares had faced headwinds throughout the year, declining roughly 12% prior to the acquisition announcement, which placed its market capitalization near $7 billion.
This transaction represents the most significant acquisition since Luke Miels assumed the CEO position from Emma Walmsley at the beginning of 2026. It marks Miels’ second major deal this year, following the $2.2 billion purchase agreement for Rapt Therapeutics completed in January.
GSK plans to finance the transaction primarily through a combination of new and existing debt facilities, supplemented by available cash reserves. The pharmaceutical giant has confirmed the deal structure will preserve its current credit rating.
Dual Late-Stage Oncology Assets Join GSK Portfolio
Nuvalent’s primary drug candidates are designed to treat non-small-cell lung cancer patients carrying specific genetic mutations — alterations commonly found in non-smoking patients. Both therapies are currently in advanced clinical trial phases with FDA regulatory decisions anticipated later in 2026.
According to GSK, both compounds demonstrate blockbuster commercial potential upon regulatory approval. Additionally, the acquisition provides GSK with an enhanced platform to advance its experimental antibody-drug conjugate Ris-Rez, which is currently undergoing late-stage clinical evaluation.
Nuvalent specializes in developing precision-targeted oncology therapies. The company’s development pipeline aligns seamlessly with Miels’ strategic vision — strengthening GSK’s late-stage cancer drug portfolio.
GSK’s oncology division posted impressive 43% growth in 2025, reaching just under £2 billion in revenue, though this represents only approximately 6% of the company’s total £32.7 billion in sales.
By comparison, competitor AstraZeneca derives 44% of its total revenue from oncology products. While GSK has considerable ground to cover, this acquisition represents a meaningful strategic advance toward narrowing that divide.
Bridging GSK’s Oncology Deficit — Learning from AstraZeneca’s Success
GSK divested its oncology assets in 2014 through an asset exchange arrangement with Novartis. Meanwhile, AstraZeneca pursued the opposite strategy, making cancer therapeutics a central focus under CEO Pascal Soriot’s leadership — a decision that delivered substantial returns.
Miels previously held executive positions at AstraZeneca. His appointment was broadly interpreted as GSK’s intention to adopt elements of that successful strategic framework.
The Nuvalent transaction will not alter GSK’s 2026 full-year financial guidance, which continues to project 7–9% core EPS growth. The company anticipates low single-digit earnings per share dilution spanning 2026 through 2028.
Revenue contributions are projected to commence in 2027, with core EPS accretion expected to materialize in 2029. After accounting for acquired cash, GSK’s net investment totals approximately $9.4 billion.
Regulatory approvals pending, the transaction is scheduled to close during the third quarter of 2026.
Miels has articulated his ambition to achieve revenue exceeding £40 billion by 2031 and fortify the development pipeline in advance of the 2028 patent expiration for HIV medication dolutegravir.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
